ESR1 and breast carcinoma: In patients with hormone receptor (HR)-positive breast cancer, which accounts for approximately 75% of breast cancers [1], endocrine therapies targeting the estrogen receptor (ER) or estrogen synthesis have reduced annual recurrences by 41% and deaths by 34%.